Samsara Inc vs Medpace Holdings Inc — how do they compare? Samsara Inc trades at $40.17 (market cap $23.49B), while Medpace Holdings Inc trades at $609.54 (market cap $16.90B). The key difference: Samsara Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Samsara Inc nearer its low. Which is the better fit depends on your goals.
| IOT | MEDP | |
|---|---|---|
Market Cap | $23.49B | $16.90B |
Sector | Technology | Technology |
52-Week High | $45.22 | $620.59 |
52-Week Low | $24.25 | $393.42 |
Enterprise Value | $22.76B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
Trailing returns across standard periods
Latest headlines on both assets
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →